Skip to main content

Market Overview

Recap: Danaher Q2 Earnings



Shares of Danaher (NYSE:DHR) fell 0.4% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 70.83% year over year to $2.46, which beat the estimate of $2.05.

Revenue of $7,218,000,000 up by 36.27% from the same period last year, which beat the estimate of $6,720,000,000.

Looking Ahead

Danaher said it expects Q3 sales growth will be in mid-to high teens percentage.

Details Of The Call

Date: Jul 22, 2021

Time: 08:00 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $287.00

52-week low: $190.34

Price action over last quarter: Up 7.32%

Company Overview

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.


Related Articles (DHR)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at